Systematic assessment of tumor necrosis at baseline in cervical cancer - An independent factor associated with poor outcome.

Cervical cancer biomarkers FIGO stage HPV Lymphocytes Macrophages PD-L1 Tumor microenvironment Tumor mutational burden Tumor necrosis

Journal

Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547

Informations de publication

Date de publication:
20 Dec 2023
Historique:
received: 06 10 2023
revised: 08 12 2023
accepted: 19 12 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 22 12 2023
Statut: aheadofprint

Résumé

Cervical cancer (CC) is a leading challenge in oncology worldwide, with high prevalence and mortality rates in young adults, most prominent in low to middle-income countries with marginal screening facilities. From the prospectively collected BioRAIDS (NCT02428842) cohort of primary squamous CC conducted in 7 European countries, a central pathology review was carried out on 294 patients' tumors. The focus was on identification of tumor-stromal characteristics such as CD8

Identifiants

DOI: 10.1016/j.humpath.2023.12.003 PMID: 38135059
pubmed: 38135059
pii: S0046-8177(23)00250-2
doi: 10.1016/j.humpath.2023.12.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Olfa Chouchane-Mlik (O)

National Center of Pathology (NCP), Laboratoire National de Santé (LNS), Dudelange, Luxembourg. Electronic address: olfa.chouchanemlik@lns.etat.lu.

Alexandra Oniga (A)

National Center of Pathology (NCP), Laboratoire National de Santé (LNS), Dudelange, Luxembourg.

Aurélien Latouche (A)

Statistical Methods for Precision Medicine, PSL Research University, Mines Paris Tech, INSERM U900, Paris, France; Conservatoire National des Arts et Métiers, Paris, France.

Maral Halladjian (M)

Department of Drug Development and Innovation, Institut Curie, PSL Research University, Paris & Saint-Cloud, France.

Felix B Kleine-Borgmann (FB)

National Center of Pathology (NCP), Laboratoire National de Santé (LNS), Dudelange, Luxembourg; Luxembourg Centre of Neuropathology (LCNP), Luxembourg.

Jean-Jacques Gérardy (JJ)

National Center of Pathology (NCP), Laboratoire National de Santé (LNS), Dudelange, Luxembourg; Luxembourg Centre of Neuropathology (LCNP), Luxembourg.

Michel Mittelbronn (M)

National Center of Pathology (NCP), Laboratoire National de Santé (LNS), Dudelange, Luxembourg; Luxembourg Centre of Neuropathology (LCNP), Luxembourg; Department of Oncology (DONC), Luxembourg Institute of Health (LIH), Luxembourg, Luxembourg; Department of Life Sciences and Medicine, University of Luxembourg, Esch sur Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Faculty of Science, Technology and Medicine (FSTM), University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Maud Kamal (M)

Department of Drug Development and Innovation, Institut Curie, PSL Research University, Paris & Saint-Cloud, France.

Suzy M Scholl (SM)

Department of Drug Development and Innovation, Institut Curie, PSL Research University, Paris & Saint-Cloud, France. Electronic address: suzy.scholl@gmail.com.

Classifications MeSH